Thymostimulin treatment in AIDS-related complex

Lucia Palmisano, Teodoro Chisesi, Massimo Galli, Francesco M. Gritti, Giuseppe Ielasi, Adriano Lazzarin, Ivano Mezzaroma, Mauro Moroni, Enzo Raise, Alberto Vaglia, Fernando Aiuti

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Thirty-four patients with AIDS-related complex (ARC) were treated for 6 months with thymostimulin, a thymic hormone. Clinical and immunological findings after a 1-year follow-up were compared with those in 24 age- and sex-matched controls receiving no immunotherapy. Statistical evaluation after 6 and 12 months showed significant differences in the two groups. The thymostimulin-treated group had higher leukocyte and lymphocyte counts, more positivity in intradermal tests with multiple recall antigens, and less lymphadenopathy and weight loss. The number of OKT3+ and OKT4+ lymphocytes decreased significantly in the control group, but did not change in the thymostimulin-treated patients. Finally, after 18 months of follow-up, no progression to AIDS was seen among the treated subjects, whereas 3 of the controls developed the disease. We conclude that thymostimulin, alone or in combination with antiviral drugs, may be helpful in the management of ARC patients.

Original languageEnglish
Pages (from-to)253-261
Number of pages9
JournalClinical Immunology and Immunopathology
Volume47
Issue number3
DOIs
Publication statusPublished - 1988

Fingerprint

AIDS-Related Complex
Thymus Hormones
Intradermal Tests
Muromonab-CD3
Lymphocyte Count
Therapeutics
Leukocyte Count
Immunotherapy
Antiviral Agents
Weight Loss
Acquired Immunodeficiency Syndrome
Lymphocytes
Antigens
Control Groups
thymostimulin

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Palmisano, L., Chisesi, T., Galli, M., Gritti, F. M., Ielasi, G., Lazzarin, A., ... Aiuti, F. (1988). Thymostimulin treatment in AIDS-related complex. Clinical Immunology and Immunopathology, 47(3), 253-261. https://doi.org/10.1016/S0090-1229(88)80003-5

Thymostimulin treatment in AIDS-related complex. / Palmisano, Lucia; Chisesi, Teodoro; Galli, Massimo; Gritti, Francesco M.; Ielasi, Giuseppe; Lazzarin, Adriano; Mezzaroma, Ivano; Moroni, Mauro; Raise, Enzo; Vaglia, Alberto; Aiuti, Fernando.

In: Clinical Immunology and Immunopathology, Vol. 47, No. 3, 1988, p. 253-261.

Research output: Contribution to journalArticle

Palmisano, L, Chisesi, T, Galli, M, Gritti, FM, Ielasi, G, Lazzarin, A, Mezzaroma, I, Moroni, M, Raise, E, Vaglia, A & Aiuti, F 1988, 'Thymostimulin treatment in AIDS-related complex', Clinical Immunology and Immunopathology, vol. 47, no. 3, pp. 253-261. https://doi.org/10.1016/S0090-1229(88)80003-5
Palmisano L, Chisesi T, Galli M, Gritti FM, Ielasi G, Lazzarin A et al. Thymostimulin treatment in AIDS-related complex. Clinical Immunology and Immunopathology. 1988;47(3):253-261. https://doi.org/10.1016/S0090-1229(88)80003-5
Palmisano, Lucia ; Chisesi, Teodoro ; Galli, Massimo ; Gritti, Francesco M. ; Ielasi, Giuseppe ; Lazzarin, Adriano ; Mezzaroma, Ivano ; Moroni, Mauro ; Raise, Enzo ; Vaglia, Alberto ; Aiuti, Fernando. / Thymostimulin treatment in AIDS-related complex. In: Clinical Immunology and Immunopathology. 1988 ; Vol. 47, No. 3. pp. 253-261.
@article{c565304d0a9b42f0910fe3351db4d823,
title = "Thymostimulin treatment in AIDS-related complex",
abstract = "Thirty-four patients with AIDS-related complex (ARC) were treated for 6 months with thymostimulin, a thymic hormone. Clinical and immunological findings after a 1-year follow-up were compared with those in 24 age- and sex-matched controls receiving no immunotherapy. Statistical evaluation after 6 and 12 months showed significant differences in the two groups. The thymostimulin-treated group had higher leukocyte and lymphocyte counts, more positivity in intradermal tests with multiple recall antigens, and less lymphadenopathy and weight loss. The number of OKT3+ and OKT4+ lymphocytes decreased significantly in the control group, but did not change in the thymostimulin-treated patients. Finally, after 18 months of follow-up, no progression to AIDS was seen among the treated subjects, whereas 3 of the controls developed the disease. We conclude that thymostimulin, alone or in combination with antiviral drugs, may be helpful in the management of ARC patients.",
author = "Lucia Palmisano and Teodoro Chisesi and Massimo Galli and Gritti, {Francesco M.} and Giuseppe Ielasi and Adriano Lazzarin and Ivano Mezzaroma and Mauro Moroni and Enzo Raise and Alberto Vaglia and Fernando Aiuti",
year = "1988",
doi = "10.1016/S0090-1229(88)80003-5",
language = "English",
volume = "47",
pages = "253--261",
journal = "Clinical Immunology and Immunopathology",
issn = "0090-1229",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Thymostimulin treatment in AIDS-related complex

AU - Palmisano, Lucia

AU - Chisesi, Teodoro

AU - Galli, Massimo

AU - Gritti, Francesco M.

AU - Ielasi, Giuseppe

AU - Lazzarin, Adriano

AU - Mezzaroma, Ivano

AU - Moroni, Mauro

AU - Raise, Enzo

AU - Vaglia, Alberto

AU - Aiuti, Fernando

PY - 1988

Y1 - 1988

N2 - Thirty-four patients with AIDS-related complex (ARC) were treated for 6 months with thymostimulin, a thymic hormone. Clinical and immunological findings after a 1-year follow-up were compared with those in 24 age- and sex-matched controls receiving no immunotherapy. Statistical evaluation after 6 and 12 months showed significant differences in the two groups. The thymostimulin-treated group had higher leukocyte and lymphocyte counts, more positivity in intradermal tests with multiple recall antigens, and less lymphadenopathy and weight loss. The number of OKT3+ and OKT4+ lymphocytes decreased significantly in the control group, but did not change in the thymostimulin-treated patients. Finally, after 18 months of follow-up, no progression to AIDS was seen among the treated subjects, whereas 3 of the controls developed the disease. We conclude that thymostimulin, alone or in combination with antiviral drugs, may be helpful in the management of ARC patients.

AB - Thirty-four patients with AIDS-related complex (ARC) were treated for 6 months with thymostimulin, a thymic hormone. Clinical and immunological findings after a 1-year follow-up were compared with those in 24 age- and sex-matched controls receiving no immunotherapy. Statistical evaluation after 6 and 12 months showed significant differences in the two groups. The thymostimulin-treated group had higher leukocyte and lymphocyte counts, more positivity in intradermal tests with multiple recall antigens, and less lymphadenopathy and weight loss. The number of OKT3+ and OKT4+ lymphocytes decreased significantly in the control group, but did not change in the thymostimulin-treated patients. Finally, after 18 months of follow-up, no progression to AIDS was seen among the treated subjects, whereas 3 of the controls developed the disease. We conclude that thymostimulin, alone or in combination with antiviral drugs, may be helpful in the management of ARC patients.

UR - http://www.scopus.com/inward/record.url?scp=0023891399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023891399&partnerID=8YFLogxK

U2 - 10.1016/S0090-1229(88)80003-5

DO - 10.1016/S0090-1229(88)80003-5

M3 - Article

C2 - 3259480

AN - SCOPUS:0023891399

VL - 47

SP - 253

EP - 261

JO - Clinical Immunology and Immunopathology

JF - Clinical Immunology and Immunopathology

SN - 0090-1229

IS - 3

ER -